Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

Table 1.

Characteristics of study participants.

More »

Table 1 Expand

Fig 1.

VLDL-cholesterol (panel A) and VLDL-triglycerides (panel B) before (baseline, filled columns) and after 12 weeks (striped columns) of PCSK9 inhibition.

Different colors indicate different patient groups. Shown are means ± SD; green: FDBL, familial dysbetalipoproteinemia; red: mixed HLP, mixed hyperlipidemia; blue: HCH, hypercholesterolemia.

More »

Fig 1 Expand

Table 2.

Lipid parameters in different patient populations before and during (12 weeks) of therapy with PCSK9 inhibitors.

More »

Table 2 Expand

Fig 2.

Cholesterol content (means) in different lipoprotein subfractions before (baseline, solid line) and after 12 weeks (dashed line) of PCSK9 inhibition.

Different colors indicate different patient groups. HCH, hypercholesterolemia; mixed HLP, mixed hyperlipidemia; FDBL, familial dysbetalipoproteinemia.

More »

Fig 2 Expand

Fig 3.

ApoB content (means) in different lipoprotein subfractions before (baseline, solid line) and after 12 weeks (dashed line) of PCSK9 inhibition.

Different colors indicate different patient groups. HCH, hypercholesterolemia; mixed HLP, mixed hyperlipidemia; FDBL, familial dysbetalipoproteinemia.

More »

Fig 3 Expand